Teva signs deal with Bioeq for ranibizumab biosimilar FYB201

Home/Pharma News | Posted 30/07/2021 post-comment0 Post your comment

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Swiss biotechnology company Bioeq AG announced on 28 June 2021 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s candidate ranibizumab biosimilar (FYB201) in Europe, Canada, Israel and New Zealand.

VEGF allaboutvision.com V21D02

Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Ranibizumab inhibits angiogenesis (the formation of new blood vessels) by inhibiting vascular endothelial growth factor A (VEGF-A), a mechanism similar to bevacizumab [1].

Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon. Bioeq will be responsible for the development, registration, and supply of the biosimilar while Teva will be responsible for commercializing the product in Europe. The companies will share revenue from the commercialization of the biosimilar.

The strategic partnership combines Teva’s long-standing commercial presence, extensive distribution network and wide-reaching sales and marketing activities across Europe and international markets with Bioeq’s capabilities in the development of biosimilars for highly regulated countries with stringent quality standards.

On 29 June 2021, Formycon and their license partner Bioeq has submitted the marketing authorization application to the European Medicines Agency (EMA) for their biosimilar version of ranibizumab, currently known as FYB201 [2].

Bioeq and Formycon have already engaged in successful pre-Biologics License Application (BLA) interactions with the US Food and Drug Administration (FDA) [3]. The BLA-submission is expected to be filed during 2021, with submission to other highly regulated territories, such as Canada, Australia, Switzerland and the UK, expected to follow shortly afterwards.

Related articles
Sandoz makes deal with Polpharma for natalizumab biosimilar

Biosimilars of ranibizumab

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Solicitudes de biosimilares bajo evaluación de la EMA - julio de 2021

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Solicitudes de biosimilares bajo evaluación de la EMA - julio de 2021

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab 
2. GaBI Online - Generics and Biosimilars Initiative. Formycon/Bioeq submit European marketing authorization for ranibizumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 30]. Available from: www.gabionline.net/biosimilars/news/formycon-bioeq-submit-european-marketing-authorization-for-ranibizumab-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Advances for Formycon and Alteogen’s eye disease biosimilar candidates [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 30]. Available from: www.gabionline.net/biosimilars/news/Advances-for-Formycon-and-Alteogen-s-eye-disease-biosimilar-candidates

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Bioeq

comment icon Comments (0)
Post your comment
Related content
Collaborations to commercialize oncology biosimilars
Cancer Cell V13I20
Home/Pharma News Posted 22/10/2021
Licensing agreements signed for ustekinumab biosimilars
IBD 1
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010